{"id":1662,"date":"2021-09-25T14:44:59","date_gmt":"2021-09-25T14:44:59","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=1662"},"modified":"2026-02-23T21:12:05","modified_gmt":"2026-02-23T21:12:05","slug":"oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/","title":{"rendered":"Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing (Contributed by Dr. Yifan Wang)"},"content":{"rendered":"<p>Pancreatic cancer is a deadly disease. Some patients develop pancreatic cancer because of an inherited change in their DNA (called a mutation). Patients with an inherited mutation may benefit from personalized medicine and their relatives may benefit from cancer screening and prevention strategies. However, there are long wait times for patients to be seen by a genetics doctor and counsellor, and many patients do not get tested for an inherited mutation. In this study, we offered genetic testing to pancreatic cancer patients directly in the cancer clinic. We showed that by using this approach, we could improve access to genetic testing and expedite return of genetic testing results to pancreatic cancer patients. However, more work is needed to increase genetic testing among the relatives of pancreatic cancer patients with an inherited mutation. (<a href=\"https:\/\/jmg.bmj.com\/content\/early\/2021\/09\/23\/jmedgenet-2021-108054\">https:\/\/jmg.bmj.com\/content\/early\/2021\/09\/23\/jmedgenet-2021-108054<\/a> )<\/p>\n<p><a href=\"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/figure-4\/\" rel=\"attachment wp-att-1663\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-1663\" src=\"https:\/\/blogs.bmj.com\/jmg\/files\/2021\/09\/Figure-300x231.png\" alt=\"\" width=\"300\" height=\"231\" srcset=\"https:\/\/blogs.bmj.com\/jmg\/files\/2021\/09\/Figure-300x231.png 300w, https:\/\/blogs.bmj.com\/jmg\/files\/2021\/09\/Figure-768x591.png 768w, https:\/\/blogs.bmj.com\/jmg\/files\/2021\/09\/Figure-640x493.png 640w, https:\/\/blogs.bmj.com\/jmg\/files\/2021\/09\/Figure.png 922w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>The Quebec Pancreas Cancer Study (QPCS) is a prospective clinic-based research registry, with an accompanying biospecimen repository, that enrols pancreas cancer patients and their relatives. The QPCS uses an integrated, in-clinic genetic counselling and genetic testing strategy to provide patients with expedited access to genetic testing. Clinicaltrials.gov Identifier: NCT04104230<!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pancreatic cancer is a deadly disease. Some patients develop pancreatic cancer because of an inherited change in their DNA (called a mutation). Patients with an inherited mutation may benefit from personalized medicine and their relatives may benefit from cancer screening and prevention strategies. However, there are long wait times for patients to be seen by [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1662","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing (Contributed by Dr. Yifan Wang) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing (Contributed by Dr. Yifan Wang) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"Pancreatic cancer is a deadly disease. Some patients develop pancreatic cancer because of an inherited change in their DNA (called a mutation). Patients with an inherited mutation may benefit from personalized medicine and their relatives may benefit from cancer screening and prevention strategies. However, there are long wait times for patients to be seen by [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-25T14:44:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-23T21:12:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/jmg\/files\/2021\/09\/Figure.png\" \/>\n\t<meta property=\"og:image:width\" content=\"922\" \/>\n\t<meta property=\"og:image:height\" content=\"710\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/09\\\/25\\\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/09\\\/25\\\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing (Contributed by Dr. Yifan Wang)\",\"datePublished\":\"2021-09-25T14:44:59+00:00\",\"dateModified\":\"2026-02-23T21:12:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/09\\\/25\\\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\\\/\"},\"wordCount\":216,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/09\\\/25\\\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2021\\\/09\\\/Figure-300x231.png\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/09\\\/25\\\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/09\\\/25\\\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/09\\\/25\\\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\\\/\",\"name\":\"Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing (Contributed by Dr. Yifan Wang) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/09\\\/25\\\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/09\\\/25\\\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2021\\\/09\\\/Figure-300x231.png\",\"datePublished\":\"2021-09-25T14:44:59+00:00\",\"dateModified\":\"2026-02-23T21:12:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/09\\\/25\\\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/09\\\/25\\\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/09\\\/25\\\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2021\\\/09\\\/Figure.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2021\\\/09\\\/Figure.png\",\"width\":922,\"height\":710},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2021\\\/09\\\/25\\\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing (Contributed by Dr. Yifan Wang)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing (Contributed by Dr. Yifan Wang) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/","og_locale":"en_US","og_type":"article","og_title":"Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing (Contributed by Dr. Yifan Wang) - JMG Contact blog","og_description":"Pancreatic cancer is a deadly disease. Some patients develop pancreatic cancer because of an inherited change in their DNA (called a mutation). Patients with an inherited mutation may benefit from personalized medicine and their relatives may benefit from cancer screening and prevention strategies. However, there are long wait times for patients to be seen by [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/","og_site_name":"JMG Contact blog","article_published_time":"2021-09-25T14:44:59+00:00","article_modified_time":"2026-02-23T21:12:05+00:00","og_image":[{"width":922,"height":710,"url":"https:\/\/blogs.bmj.com\/jmg\/files\/2021\/09\/Figure.png","type":"image\/png"}],"author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing (Contributed by Dr. Yifan Wang)","datePublished":"2021-09-25T14:44:59+00:00","dateModified":"2026-02-23T21:12:05+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/"},"wordCount":216,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2021\/09\/Figure-300x231.png","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/","url":"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/","name":"Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing (Contributed by Dr. Yifan Wang) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2021\/09\/Figure-300x231.png","datePublished":"2021-09-25T14:44:59+00:00","dateModified":"2026-02-23T21:12:05+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/#primaryimage","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2021\/09\/Figure.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2021\/09\/Figure.png","width":922,"height":710},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2021\/09\/25\/oncology-clinic-based-germline-genetic-testing-for-exocrine-pancreatic-cancer-enables-timely-return-of-results-and-unveils-low-uptake-of-cascade-testing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing (Contributed by Dr. Yifan Wang)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=1662"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1662\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=1662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=1662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=1662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}